Compare Crispr Therapeutics AG (CRSP) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Strategy Inc. — how do they compare? Crispr Therapeutics AG trades at $51.44 (market cap $4.88B), while Strategy Inc. trades at $154.8 (market cap $60.40B). The key difference: Strategy Inc. is far larger — about 12.4× Crispr Therapeutics AG's market cap, and Strategy Inc. is more actively traded (23,421,830 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Strategy Inc. for 112 Days on average.
| CRSP | MSTR | |
|---|---|---|
Market Cap | $4.88B | $60.40B |
Volume | 2,861,747 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $74.92 | $320.29 |
52-Week Low | $44.34 | $82.31 |
Typical Hold Time | 77 Days | 112 Days |
Enterprise Value | $3.30B | $79.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
MSTR stock trades at $153.37, down 6.79% today, reflecting volatility despite a bullish technical signal. The company reported a net loss of $3.85B in 2025 with a negative net income margin of -6,102.96%, though revenue grew slightly to $477.23M. Analyst consensus remains optimistic with a $252 price target, but earnings misses in recent quarters highlight operational challenges.
The outlook hinges on improving profitability and Bitcoin market stability, offering upside if earnings rebound. Key risks include persistent losses, high debt, and sensitivity to macroeconomic factors. Investors should weigh analyst optimism against fundamental weaknesses before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
